Emerging therapeutic targets in bladder cancer

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• Muscle invasive urothelial bladder carcinoma (BCa) presents significant treatment challenges.
• Comprehensive genomic profiling of tumors is crucial for identifying actionable molecular drivers.
• Understanding these drivers can reveal novel therapeutic targets for BCa.

Purpose of the Study:

• To review molecular drivers of the malignant phenotype in BCa.
• To discuss emerging therapeutic agents targeting these drivers.
• To highlight novel treatment strategies for BCa.

Main Methods:

• Review of current literature on molecular drivers in BCa.
• Analysis of preclinical and clinical data for targeted therapies.
• Discussion of emerging treatment modalities including small molecule inhibitors and immunotherapies.

Main Results:

• Activating FGFR mutations/translocations show efficacy with pan-FGFR inhibitors.
• mTOR inhibitors and PI3K/MEK targeting are strategies for TSC1 mutations.
• Ado-trastuzumab emtansine (T-DM1) shows promise for HER2-positive BCa.
• Investigational inhibitors of cell cycle regulators (aurora kinase, PLK1, CDK4) are studied with chemotherapy.
• Anti-CTLA4 and anti-PDL1 therapies are emerging as potent immunomodulating treatments for BCa.

Conclusions:

• Novel therapeutic targets and agents, including FGFR inhibitors, T-DM1, and immunotherapies, hold significant promise.
• Targeted therapies and combination strategies are advancing BCa treatment.
• These advancements offer hope for improved outcomes in patients with BCa.